A Pharmacodynamic Study of Vismodegib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC) With Accessible Metastatic Lesions for Tumor Biopsy
Phase of Trial: Phase 0
Latest Information Update: 27 Jul 2018
Price : $35 *
At a glance
- Drugs Vismodegib (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 05 Oct 2017 Status changed from active, no longer recruiting to completed.
- 14 Oct 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017.